menu ☰
menu ˟

FDA grants breakthrough designation to NiCord for bone marrow transplantation

11 Oct 2016
The FDA granted breakthrough therapy designation to the novel graft modality NiCord for bone marrow transplantation in patients with hematological malignancies, according to the modality’s manufacturer.NiCord (Gamida Cell) — an ex vivo expanded c...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.